Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical recombinant epidermal growth factor for psoriasis
IRCT20141007019432N8Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of epidermal growth factor in psoriasis (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Change from baseline in target lesion severity score. Started Apr 2022; status: completed.
02
Drugs
epidermal growth factor
03
Conditions
psoriasis
Beyond the preview
Go deeper on IRCT20141007019432N8.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20141007019432N8.